The chart of the week focuses on the use of GLP-1 shots, such as Ozempic and Wegovy. The chart shows states with obesity rates of 35% or higher, mostly in the central US and the middle to southern East Coast and is marked by the stripes across them. Darker shades of red by each state on the chart represent higher percentages of prescriptions covered by insurance for these drugs. However, it’s important to note that many people also pay out of pocket or use generic versions, which wouldn’t be included in this chart. These drugs are frequently discussed in investment circles due to their remarkable success, and the future prospects are promising. Uses for these drugs could also go beyond weight loss with studies underway to explore potential applications for treating alcoholism. Novo Nordisk, based in Denmark, developed Ozempic, and as of the end of July 2024, their stock price has risen by over 66% in the past year and almost 130% in the last 3 years.